We’re excited to announce that Fulcrum Neuroscience has been admitted to the GNPC—making it one of the first analytics companies to join a consortium including leading pharmaceutical and academic research organizations. The GNPC is a global collaborative platform dedicated to accelerating neurodegenerative research by harnessing cutting‐edge proteomics technologies to uncover novel biomarkers and therapeutic targets. With Fulcrum’s advanced analytics capabilities now on board, this partnership promises to further drive breakthroughs in understanding complex conditions like Alzheimer’s and Parkinson’s disease. Stay tuned for more updates as this innovative alliance works to transform the landscape of neuroscience research.